Department of Neonatal Medicine, The Royal Hospital for Sick Children, Glasgow, Scotland, UK.
Acta Paediatr. 2013 Mar;102(3):254-7. doi: 10.1111/apa.12103. Epub 2013 Jan 4.
To examine the relationship between early duct diameter and patent ductus arteriosus (PDA) symptoms.
A retrospective study of infants <29 weeks of gestation with early colour Doppler assessment of PDA diameter, in whom PDA was managed conservatively, without cyclo-oxygenase inhibitor (COI) treatment.
Gestation and birthweight, [median (range)], were 26 (23-28) weeks and 865 (500-1440) g, respectively. Symptomatic PDA developed in 20 (68.9%) infants, with 11 (37.9%) referred for PDA ligation at 24 (17-30) days. Symptoms resolved spontaneously in 7 infants (24.1%) at 19 (7-32) days. There were 6 (20.7%) deaths, including four early neonatal deaths with large PDA. Early colour Doppler PDA diameter >1.5 mm (n = 20) predicted development of symptomatic PDA (sensitivity 91%, specificity 100%), but symptoms resolved spontaneously without treatment in 30%. There was a significant linear correlation (p < 0.001) with increasing early PDA diameter and the development of more persistent PDA symptoms, early neonatal mortality and morbidity.
In our (COI)-naïve population, the mortality and morbidity associated with prolonged exposure to unrestricted ducts are high. Not all infants with early PDA diameter >1.5 mm have persistent symptomatic PDA, but early PDA diameter could be utilized to identify those infants at greatest risk of adverse outcome associated with PDA.
探讨早期动脉导管直径与动脉导管未闭(PDA)症状之间的关系。
回顾性研究了 29 周以下胎龄、早期彩色多普勒评估动脉导管直径的婴儿,这些婴儿接受了保守治疗,未使用环氧化酶抑制剂(COI)治疗。
胎龄和出生体重中位数(范围)分别为 26(23-28)周和 865(500-1440)g。20 名(68.9%)婴儿出现症状性 PDA,其中 11 名(37.9%)在 24(17-30)天时因 PDA 结扎而转诊。7 名(24.1%)婴儿在 19(7-32)天时自发性缓解症状。有 6 名(20.7%)死亡,包括 4 名因大 PDA 导致的早期新生儿死亡。早期彩色多普勒 PDA 直径>1.5mm(n=20)预测出现症状性 PDA(敏感性 91%,特异性 100%),但未经治疗 30%的婴儿症状可自行缓解。早期 PDA 直径与持续性 PDA 症状、早期新生儿死亡率和发病率之间存在显著线性相关性(p<0.001)。
在我们(未使用 COI)的人群中,长时间暴露于未受限制的动脉导管与较高的死亡率和发病率相关。并非所有早期 PDA 直径>1.5mm 的婴儿都有持续性症状性 PDA,但早期 PDA 直径可用于识别那些与 PDA 相关不良结局风险最高的婴儿。